N-terminal pro-brain natriuretic peptide superiority for prognosis of major adverse cardiovascular events in patients with acute myocardial infarction without heart failure

Rada Vučić; Vladimir Ignjatović; Olivera Andrejić; Katarina Čupić; Miodrag Srećković; Filipović Vučković; Marija Sekulić; Milan Dobrić; Jelena Rakočević

doi:10.5937/afmnai42-53487

Research paper

Published: 01.12.2024.

<< Prev | Next >>

PDF

https://doi.org/10.5937/afmnai42-53487

N-terminal pro-brain natriuretic peptide superiority for prognosis of major adverse cardiovascular events in patients with acute myocardial infarction without heart failure

Abstract

Many markers are used to evaluate the prognosis in patients with acute myocardial infarction (AMI). Researches are focused on available markers with high sensitivity and specificity. The aim of our study was to evaluate the prognostic value of N-terminal pro brain natriuretic peptide (NT-proBNP) and its superiority compared with other prognostic markers in patients with AMI. Sixty-six patients with the diagnosis of AMI were enrolled in the study. The evaluated variables were: symptoms, cardiovascular risk factors, laboratory analyses (including NT-proBNP), GRACE risk score, electrocardiography, left ventricular ejection fraction (LVEF) and coronary angiography. One and six-month major adverse cardiovascular events (MACE) included: reAMI, heart rhythm disorders, acute heart failure, stroke, fatal event. Patients with one-month and six-month MACE were older, had anterior AMI, higher levels of NT-proBNP, urea, creatinine, lower LVEF, creatinine clearance (CCr) and hemoglobin level. NT-proBNP is an independent predictor of short-term (p = 0.002) and long-term (p = 0.000) prognosis. Its cut point of 1,467 pg/ml is a significant independent predictor of one-month MACE and cut point of 996 pg/ml is a significant independent predictor of six-month MACE. NT-proBNP is a strong short-term and long-term predictive marker in AMI patients without heart failure.

References

Nasution SA, Perkasa H, Ginanjar E, Rinaldi I. In-Hospital Major Adverse Cardiac Events Factor Predictors on ST-Elevation Myocardial Infarction after Primary Percutaneous Coronary Intervention at dr. Cipto Mangunkusumo General Hospital. eJournal Kedokteran Indonesia. 10(2):107–13.

Jernberg T, Lindahl B, Siegbahn A, Andren B, Frostfeldt G, Lagerqvist B, et al. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. Journal of the American College of Cardiology. 2003;42(11):1909–16.

James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, et al. N -Terminal Pro–Brain Natriuretic Peptide and Other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients With Unstable Coronary Artery Disease. Circulation. 2003;108(3):275–81.

Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. Journal of the American College of Cardiology. 2002;40(3):437–45.

Sykes R, Doherty D, Morrow A, Mangion K, Rushd A, Berry C. NT-proBNP in patients presenting with myocardial infarction and non-obstructive coronary arteries without left ventricular systolic dysfunction. American Heart Journal Plus: Cardiology Research and Practice. 2023;33:100311.

Shen S, Ye J, Wu X, Li X. Association of N-terminal pro-brain natriuretic peptide level with adverse outcomes in patients with acute myocardial infarction: A meta-analysis. Heart & Lung. 2021;50(6):863–9.

Jering KS, Claggett BL, Pfeffer MA, Granger CB, Køber L, Lewis EF, et al. Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial. Circulation: Heart Failure. 2023;16(5).

Velders MA, Wallentin L, Becker RC, van Boven AJ, Himmelmann A, Husted S, et al. Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial. American Heart Journal. 2015;169(6):879-889.e7.

Jeong JH, Lee KS, Park SM, Kim SR, Kim MN, Chae SC, et al. Prediction of longitudinal clinical outcomes after acute myocardial infarction using a dynamic machine learning algorithm. Frontiers in Cardiovascular Medicine. 11.

10.

Wang J, Gao W, Chen G, Chen M, Wan Z, Zheng W, et al. Biomarker-based risk model to predict cardiovascular events in patients with acute coronary syndromes – Results from BIPass registry. The Lancet Regional Health - Western Pacific. 2022;25:100479.

11.

Felker GM, Shaw LK, O’Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. Journal of the American College of Cardiology. 2002;39(2):210–8.

12.

Li N, Chen R, Li J, Zhao X, Wang Y, Zhou J, et al. Prognostic significance of serial N-terminal pro-B-type natriuretic peptide levels in patients with acute myocardial infarction: A prospective study. American Heart Journal. 2023;262:90–9.

13.

Tsai IT, Wang CP, Lu YC, Hung WC, Wu CC, Lu LF, et al. The burden of major adverse cardiac events in patients with coronary artery disease. BMC Cardiovascular Disorders. 2017;17(1).

14.

Cai A, Dillon C, Hillegass WB, Beasley M, Brott BC, Bittner VA, et al. Risk of Major Adverse Cardiovascular Events and Major Hemorrhage Among White and Black Patients Undergoing Percutaneous Coronary Intervention. Journal of the American Heart Association. 2019;8(22).

15.

O’Donoghue ML, Morrow DA, Cannon CP, Jarolim P, Desai NR, Sherwood MW, et al. Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. Journal of the American Heart Association. 2016;5(5).

16.

Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD. N-Terminal Pro–B-Type Natriuretic Peptide Levels for Dynamic Risk Stratification of Patients With Acute Coronary Syndromes. Circulation. 2004;110(20):3206–12.

17.

Omland T. Clinical and Laboratory Diagnostics of Cardiovascular Disease: Focus on Natriuretic Peptides and Cardiac Ischemia. Scandinavian Journal of Clinical and Laboratory Investigation. 2005;65(sup240):18–24.

18.

Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). European Heart Journal. 2019;40(3):237–69.

19.

Vucic RM, Andrejic OM, Stokanovic D, Stoimenov TJ, McClements L, Nikolic VN, et al. Galectin-3 as a Prognostic Biomarker in Patients with First Acute Myocardial Infarction without Heart Failure. Diagnostics. 13(21):3348.